Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 1/20 | 0.59 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.59 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.59 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 8/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7113055 | 1.00 | ABCC9 (0.59) | ABCC9ABCC8KCNJ11LY96MAPT | |
| SCHEMBL7107471 | 0.93 | LY96 (0.52) | ABCC9ABCC8KCNJ11LY96MAPT | |
| SCHEMBL7107467 | 0.93 | LY96 (0.52) | ABCC9ABCC8KCNJ11LY96MAPT | |
| SCHEMBL7108290 | 0.93 | LY96 (0.52) | ABCC9ABCC8KCNJ11LY96MAPT | |
| SCHEMBL7108288 | 0.93 | LY96 (0.52) | ABCC9ABCC8KCNJ11LY96MAPT | |
| SCHEMBL5578528 | 0.93 | ABCC9 (0.53) | ABCC9ABCC8KCNJ11LY96MAPT | |
| SCHEMBL7112801 | 0.93 | ABCC9 (0.53) | ABCC9ABCC8KCNJ11LY96MAPT | |
| SCHEMBL7114348 | 0.92 | LY96 (0.57) | ABCC9ABCC8KCNJ11LY96MAPT | |
| SCHEMBL7114351 | 0.92 | LY96 (0.57) | ABCC9ABCC8KCNJ11LY96MAPT | |
| SCHEMBL7112818 | 0.91 | PTGER4 (0.51) | ABCC9ABCC8KCNJ11LY96MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | DARA BIOSCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | DARA BIOSCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | DARA BIOSCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| EP-1183236-B1 | CINNAMOYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES | AVENTIS PHARMA GMBH (DE) | 2003-10-22 | — | — | EP | disclosed |
| EP-1183236-A1 | CINNAMOYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES | Aventis Pharma Deutschland GmbH (DE) | 2002-03-06 | — | — | EP | disclosed |
| US-6350778-B1 | CARDIOVASCULAR DISORDERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-02-26 | — | — | US | disclosed |
| WO-2000071513-A1 | CINNAMOYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | PYGB, PC, KCNN3 | ABCC9 384/4885ABCC8 415/4885KCNJ11 18/4885 |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | PC, LIPE, ATP5ME | ABCC9 482/4885ABCC8 605/4885KCNJ11 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.